Portage Biotech (ALP) Stock Price, News & Analysis

Company Overview

Portage Biotech Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology treatments for cancer. The company’s approach is designed to stimulate the immune system and promote targeted destruction of tumor cells, with the goal of addressing cancers that may be difficult to treat with conventional therapies.

Portage’s lead investigational product is INT230-6, an intratumoral therapy licensed from Intensity Therapeutics. The treatment is designed to deliver anticancer agents directly into tumors and may also activate an immune response against cancer cells elsewhere in the body. INT230-6 has been evaluated in clinical studies involving patients with advanced solid tumors, including breast cancer and sarcoma.

Portage Biotech was formed through a series of corporate transactions involving biotechnology and investment entities and is incorporated in the British Virgin Islands. Its development activities have involved clinical research and collaborations across North America and other international markets. Ian Walters has served as the company’s chief executive officer and a director. The company’s common shares trade on the Nasdaq Capital Market under the ticker symbol PRTG.

Key Stats

• Today's Range: $3.09 to $3.44
• 50-Day Range: $2.95 to $5.75
• 52-Week Range: $2.78 to $199.50
• Volume: 14,947 shs
• Average Volume: 31,053 shs
• Market Capitalization: $4.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.50
• Consensus Rating: Reduce

Portage Biotech Stock Analysis - MarketRank™

Portage Biotech scored higher than 67% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Reduce

Consensus Rating

Portage Biotech has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Portage Biotech has a consensus price target of $12.50, representing about 303.2% upside from its current price of $3.10.

Amount of Analyst Coverage

Portage Biotech has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Portage Biotech are expected to grow in the coming year, from ($14.00) to ($8.50) per share.

Price to Book Value per Share Ratio

Portage Biotech has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.48% of the float of Portage Biotech has been sold short.

Short Interest Ratio / Days to Cover

Portage Biotech has a short interest ratio ("days to cover") of 4.79.

Change versus previous month

Short interest in Portage Biotech has recently increased by 2.18%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Portage Biotech does not currently pay a dividend.

Dividend Growth

Portage Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Portage Biotech has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Technology companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Portage Biotech this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 1 people have added Portage Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

3 insiders have purchased shares of Portage Biotech in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $254,815.00 in company stock, which represents 5.3031% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Portage Biotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $254,815.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

13.36% of the stock of Portage Biotech is held by institutions.

Company Calendar

• Last Earnings: 7/16/2026
• Today: 11/12/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Technology
• Industry: IT Services
• Sub-Industry: Internet Services & Infrastructure
• Current Symbol: NASDAQ:ALP
• Previous Symbol: NASDAQ:ATON
• CIK: 1095435
• Web: alphacompute.ai
• Phone: (416) 737-7600
• Fax: N/A
• Employees: 22
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Portage Biotech: $12.50
• High Price Target: $12.50
• Low Price Target: $12.50
• Potential Upside/Downside: +303.2%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 0.31
• Quick Ratio: 0.31

Sales & Book Value

• Annual Sales: $100 thousand
• Price / Sales: 48.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.90 per share
• Price / Book: 0.22

Miscellaneous

• Outstanding Shares: 1,550,000
• Free Float: N/A
• Market Cap: $4.81 million
• Optionable: N/A
• Beta: 0.65